CMI-392 is primarily used in the field of pharmaceuticals, where it serves as a key compound in the development of therapeutic agents. Its application is particularly notable in the treatment of certain types of cancers, where it has shown efficacy in inhibiting specific pathways that are crucial for tumor growth and survival. Additionally, CMI-392 is being explored for its potential in addressing autoimmune diseases, as it modulates immune responses that are often dysregulated in such conditions. Researchers are also investigating its role in neuroprotective therapies, where it may help in mitigating damage caused by neurodegenerative disorders. The compound's versatility and targeted action make it a valuable asset in ongoing medical research and drug development.